Human and Experimental Toxicology (HET), an international peer reviewed journal, is dedicated to publishing preclinical and clinical original research papers and in-depth reviews that comprehensively cover studies of functional, biochemical and structural disorders in toxicology. The principal aim of the HET is to publish timely high impact hypothesis driven scholarly work with an international scope.
The journal publishes on:
Structural, functional, biochemical, and molecular effects of toxic agents
Studies that address mechanisms/modes of toxicity
Safety evaluation of novel chemical, biotechnologically-derived products, and nanomaterials for human health assessment including statistical and mechanism-based approaches
Novel methods or approaches to research on animal and human tissues (medical and veterinary patients) investigating functional, biochemical and structural disorder
in vitro techniques, particularly those supporting alternative methods
Papers submitted will be judged on the basis of scientific originality and contribution to the field and quality and subject matter. Authors must clearly identify chemically the material tested and briefly explain what novel toxic effect (s) or toxic mechanism (s) of the chemical are being reported and what their significance is.
HET will not accept case reports and case studies. HET will not accept papers on herbal or other extracts unless sufficient chemical characterization of the material under investigation is supplied.
Studies must address at least one of the following:
Adverse effects induced by a chemically defined substance and/or the mechanism underlying the toxic phenomenon
New techniques for assessing potential toxicity, including molecular and systems biology
Toxicological examinations of specific chemicals, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability
Only papers that have not been previously published, that fit in the above mentioned scope, and that have been reviewed by experts in the field prior to publication will be accepted. Cover letters must state that the paper is new and original and is not under consideration for publication elsewhere. Papers pending in other journals will not be considered. Co-authors should be individuals who have contributed substantially to the content of the papers. All authors must declare any potential conflict of interest and all financial support.

Editor-in-Chief
Kai Savolainen
NanoReflections Oy, Finland
Editor (Americas)
A Wallace Hayes
Michigan State University and University of South Florida, USA
Editorial Board
Susan M. Barlow
Independent Consultant, UK
Nursen Basaran
Haceteppe University, Turkey
Barbara D. Beck
Gradient Corporation, Cambridge, USA
Bas J. Blaauboer
University of Utrecht, Netherlands
A R Boobis
Imperial College London, UK
Edward J. Calabrese
University of Massachusetts, USA
Daniel A. Casciano
NCTR, USA
J K Chipman
University of Birmingham , UK
Emanuela Corsini
University of Milan, Italy
F.A. De Wolff
Leiden University, Netherlands
Michael L. Dourson
Toxicology Excellence for Risk Assessment, USA
S.J.S. Flora
National Institute of Pharmaceutical Education and Research, India
Sidney Green
Howard University, USA
Helmut Greim
Technical University of Munich, Germany
Mary Gulumian
NIOH, South Africa
E.S. Harpur
Newcastle University, UK
Kenneth Hartigan-Go
Department of Health Manila, Philippines
Philip Harvey
Independent Consultant, UK
Ivo Iavicoli
University of Naples Federico II, Italy
Salmann H. Inayat-Hussain
Petroliam Nasional Berhad, Malaysia
Thomas A. Lewandowski
Gradient, USA
Timothy C. Marrs
Food Standards Agency, UK
Professor John O'Brien
Danone Vitapole, France
Yasumitsu Ogura
Chiba University, Japan
B. Kevin Park
University of Liverpool, UK
Camilla Pease
Unilever Colworth, UK
Chada S. Reddy
University of Missouri-Columbia, USA
Ivonne M.C.M. Rietjens
Wageningen University, Netherlands
Tetsuo Satoh
Chiba University, Japan
B. Schilter
Nestle Research Center, Switzerland
Roel Schins
Heinrich-Heine-University Dusseldorf, Germany
Bryan K. Shipp
Pfizer Inc., USA
Aristidis Tsatsakis
University of Crete, Greece
G.B. Van De Voet
Leiden University, Netherlands
Secretary
Leila Ahlstrom
Finnish Institute of Occupational Health, Finland